Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.

Abstract

The US FDA approved eltrombopag for use among certain patients with chronic ITP based upon demonstration of a favorable risk-to-benefit profile, where the major benefit pertained to demonstration of a clinically important increase in blood platelets among a population of patients relatively refractory to prior therapies.